Craif Inc.
PrivateLast Round
Series D
Aug 18, 2026
Est. Valuation
$100M
Total Funding Raised
$55M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Craif Inc. operates in Healthcare & Life Sciences and is based in Tokyo. Its latest recorded funding round was a Series D round in August 2026.
Craif Inc. is a biotechnology company that develops and provides exosome-based liquid biopsy tests and AI-driven diagnostic platforms for early cancer detection.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI
Business Model
B2B2C
Customer Profile
Usage-Based SaaS, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Craif Inc. Comparables
Compare Craif Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HIROTSU BIO SCIENCE INC. | 81% | |
| Nucleix | 74% | |
| Mirxes | 74% |
For institutional investors. Book with your work email.
Craif Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 18, 2026 | ||||
| IPO | Dec 8, 2025 | ||||
| Series C | Apr 28, 2025 | ||||
| Series B Extension | Apr 12, 2022 | ||||
| Series B | Nov 2, 2021 | ||||
Series A | Jun 17, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Craif Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mori Trust Co., Ltd. | Series A |
| Tokio Marine & Nichido Fire Insurance | Series B Extension, Series B |
| Saisei Ventures | Series B Extension |
| Unreasonable Collective | Series C |
| 株式会社日本政策金融公庫 | Series D |
| Joyo Bank, Ltd. | Series D |
| Global Brain Corporation | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 18, 2026
$33M round led by TAUNS Laboratories, Inc.
- May 27, 2026
Achieved over 3x annual growth since product release in 2022.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 20, 2026
Craif, Inc. develops a urine analysis platform for the early detection of multiple diseases, initially focusing on cancer, while building a large urine dataset and preparing a Japanese regulatory filing for an AI-powered pancreatic cancer test, as of Aug 20th '26.
- launchesAug 18, 2026
Craif, Inc. plans a reimbursement-driven launch in the United States for its non-invasive urine-based cancer test, which uses artificial intelligence to analyze microRNA and is already offered at more than 2,500 medical institutions and 4,500 pharmacies across Japan.
- launchesAug 18, 2026
Craif, Inc. prepares for a reimbursement-driven launch of its urine-based cancer detection platform in the United States, which uses artificial intelligence to analyze microRNA for non-invasive cancer detection.
- receives_financingAug 18, 2026
Craif, Inc. receives $33M in Series D financing on Aug 18th '26, co-led by Granite-Integral and Tauns to fund a prospective pancreatic cancer study and expand its U.S. clinical team in California.
- receives_financingAug 18, 2026
On Aug 18th '26, Craif, Inc. closes an approximately $34 million Series D round, including $3.3M in debt, co-led by Granite-Integral and Tauns Co., Ltd., to fund U.S. research and development, Japanese regulatory work and preparations for a U.S. cancer-test launch.
For institutional investors. Book with your work email.
Craif Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Craif Inc.'s valuation, stock price, and market status.
Is Craif Inc. a public or private company?
Craif Inc. is a private company.
What is the current stock price of Craif Inc.?
Craif Inc. is a private company, so its shares have no public market price. Caplight tracks Craif Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Craif Inc. worth (valuation)?
Craif Inc.'s valuation is estimated at $100.0M based on funding round data.
Can I buy Craif Inc. stock?
Craif Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Craif Inc.'s last funding round?
Craif Inc.'s most recent funding round was Series D on August 18, 2026.
Who are the main investors in Craif Inc.?
Key investors in Craif Inc. include Daiwa Corporate Investment Co., Ltd., X&KSK.
Will Craif Inc. IPO soon?
No public IPO plans have been announced for Craif Inc..
How can I track Craif Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Craif Inc.'s shares on secondary markets.